The sale, valued at roughly $545,000, was carried out through a Rule 10b5‑1 plan that Chapman amended in March 2026. Such plans allow insiders to schedule sales in advance, insulating the transactions from accusations of trading on material non‑public information.
Following the disposition, Chapman retains a direct stake of about 98,199 shares, representing roughly 0.06% of Natera’s total equity, and continues to hold derivative securities that preserve his economic interest in the company’s performance.
Natera’s stock has surged dramatically over the past year, posting a 91% total return as of the transaction date, far outpacing the S&P 500’s roughly 15% gain in the same period. The share price closed at $361.74 on the day of the filing, a modest premium to the $320.99 average sale price.
Analysts remain cautiously optimistic. The median one‑year price target from 24 analysts is $350, implying a slight downside from the current price, while the highest target of $435 suggests upside potential of about 20%. The lowest target of $280 would signal a 22% decline.
Natera, valued at about $52.1 billion, generates revenue through its portfolio of molecular diagnostic tests—including Panorama for non‑invasive prenatal screening, Vistara for single‑gene disorder detection, and Horizon for carrier screening—primarily via per‑test fees and volume contracts with obstetric, gynecology and reproductive‑endocrinology practices worldwide.
Despite reporting a trailing‑twelve‑month net loss of $192.3 million, the company posted $2.7 billion in revenue, reflecting strong growth and expanding market adoption of its diagnostics‑as‑a‑service model.